Topic: Policy: Rebates

Alternative Models for Pharmaceutical Rebates

Dec 2018 | Policy Paper

The combination of rising drug costs at the health system level and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. Drug makers in the US face no federal process whereby prices are evaluated in comparison to evidence of clinical benefit, but they must negotiate […]